相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Victor M. Rivera et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel
C. Sessa et al.
ANNALS OF ONCOLOGY (2010)
Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine
Antonella Perotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
Terence O'Reilly et al.
TRANSLATIONAL ONCOLOGY (2010)
A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
Christine M. Hartford et al.
CLINICAL CANCER RESEARCH (2009)
Targeting the mTOR pathway using deforolimus in cancer therapy
Devalingam Mahalingam et al.
FUTURE ONCOLOGY (2009)
Targeting the mTOR Signaling Network for Cancer Therapy
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
Sherif S. Farag et al.
LEUKEMIA RESEARCH (2009)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dose selection in phase I studies: Why we should always go for the top
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Proliferation signal inhibitors in transplantation: Questions at the cutting edge of everolimus therapy
J. R. Chapman et al.
TRANSPLANTATION PROCEEDINGS (2007)
Pim family kinases enhance tumor growth of prostate cancer cells
WW Chen et al.
MOLECULAR CANCER RESEARCH (2005)
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
A Boulay et al.
CANCER RESEARCH (2004)
The TOR pathway: A target for cancer therapy
MA Bjornsti et al.
NATURE REVIEWS CANCER (2004)
Regulation of translation initiation by FRAP/mTOR
AC Gingras et al.
GENES & DEVELOPMENT (2001)
Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies
I Mothe-Satney et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
